Introduction
A survey on Singaporean venture capital, government's incentives to attract venture capital and intellectual property (IP) law was sent to all biotechnology stakeholders in Singapore between 20 March and 10 April 2006. Many individually expressed their confidential views. These were collected and presented in this article. The survey participants were asked to rate (a rating of 1 being the lowest and 10 being the highest) on the availability of Singaporean venture capital, Singapore government funding, the robustness of Singapore's IP law and the robustness of the Singaporean regulatory regime.
Venture Capital
The survey results are presented in Tables 1 and 2 . Most stakeholders identified the main source of Singapore's biotechnology venture capital as the Singapore government (Table 2) . However, biotechnology investments are long term in reaping rewards and private venture capitalists probably prefer to invest in fields whereby the return timeline is closer. In addition, there is a lack of specialists in Singapore who are qualified to validate and value biotechnology companies. This lacuna stems from the fact that there is no way biotechnology companies can get listed (IPO) in Singapore unless they are profitable. However, with a S$5 billion (US$3.1 billion) national research fund, there will be more funding opportunities for Singapore biotech companies.
The private venture capital investment in the biotechnology field has been, until recently, minimal and the capital investment trends tend to be overly cautious. Most survey participants feel that the Singapore financial sector and the venture capitalists there lack the expertise in evaluating and understanding biotechnology, therefore, the Singapore government needs to provide more training and incentives in this area. The Singapore biotechnology industry needs to attract venture capitalists. The Singapore government could outsource some of its funds to private fund managers specifically for biotechnology. The Singapore government should leave some room for international venture capitalists to invest. The Singapore venture capitalists tend to be more conservative as compared to their western counterparts. Most stakeholders are hoping that more venture capitalists will take the first step and invest in biotechnology in Singapore.
The Singapore government and BioSingapore should set up more meetings/forum/industry networking events between Singapore biotechnology companies and venture capitalists to facilitate communication and interaction. This would engender confidence in venture capitalists and increase the awareness of the biotech companies. Some survey participants feel that the Singapore government is tackling the venture capital problem by inviting multinationals to inject their own funds. Even here, the government is regarded as being too calculating and overly cautious in the funding of the projects.
Some survey participants feel that there needs to be a change in attitude. The government-linked companies have a tendency to move into profitable areas leaving little scope for the survival of Small and Medium-sized Enterprise (SMEs). 
Intellectual Property (IP) Law
It must be stated from the start of this topic that no legal opinions are being expressed in relation to its accuracy (in a technical legal sense) of the views of the survey participants in relation to intellectual property law.
The integrity of the Singapore IP law is regarded by many survey participants as being comparable to jurisdictions in the Europe, the US, Japan and Australia and most participants are satisfied with the state of Singapore's current legislative provisions.
Many stakeholders feel that the Singapore IP law and its enforcement regime is one of the strongest in the Asia Pacific (Table 3) . However, they regard the main problem as the lack of expertise of Singaporeans working in the IP field. Out of approximately 100 Singapore-registered patent agents, less than 20 have a technical background. The remainder hold a law degree (without any technical expertise) and with almost no experience in patents.
Biotechnology expertise in the legal industry is relatively rare (with only several professional patent attorneys). A lack of experience in the litigation of IP cases by the law firms in Singapore and the lack of expertise in the strategic management of IP portfolios for biomedical and pharmaceuticals companies and the government is a major concern for stakeholders.
A more concentrated and synergistic effort is needed between IP lawyers, companies, venture capitalists, inventors, scientists and the government to ensure effective IP protection. 
Regulatory Law
Most stakeholders feel that the Singapore IP law and regulatory bodies are currently sufficient (Table 4) . They feel that the Singapore IP law is on par with other countries and better than some countries. Singapore is well known for its strict regulatory regime and its enforcement processes. Its relevant healthcare and pharmaceutical regulatory agencies are respected in the Asia Pacific.
The legislation pertaining to pre-clinical trial research is particularly effective and rational. The current Singapore legislation supports stem cell research. However, amendments are required for stock exchange listing requirements to enable non-profitable companies to be listed on the Singapore Stock Exchange. In addition, the Singapore laws need to be amended to accommodate developments in medical devices, herbal medicine, some biological areas and pre-clinical and clinical trials. The regulatory bodies have already moved towards this direction.
Some responses stated that Singapore embraces global GM technology. As China and India will pose a major competitor in GM agricultural biotechnology, they are expecting more Singaporeans to accept GM foods by 2010.
Other participants' comments include the high turnover rates of young officers at the Ministry of Health (MOH) and MNCs. They suggest that incentives can be implemented to entice young officers to stay longer. Some survey participants indicated that the Singapore biotechnology sector has a bleak outlook for 2010 as Singapore cannot afford to implement a manufacturing style mentality of past successes and expect to successfully transpose it onto the high tech biotech sector. There needs to be a drastic leadership and middle management change in all of its institutions if Singapore biotechnology is to survive the global biotechnology challenge. With heavy government and private investment in the Singapore biotechnology sector, all stakeholders are expecting positive results, however, given the high risk profile, there will also be failures and financial losses by 2010. Some members felt that they could not be optimistic unless areas of weakness as indicated in the SWOT analysis paper (Survey Commentaries and Analysis on SWOT analysis of Singapore Biotechnology Boom Indicators by Dr Morley Muralitharan, Sebastian Agricola and Dr Stephen Chandler) are specifically addressed.
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